丙酚替诺福韦治疗慢性乙型肝炎的临床疗效.

Objective to observe the efficacy and safety in the clinic practice of Propofol Tenofavir Fumarate (TAF) as a treatment of Chronic Hepatitis B (CHB) Method A total of 180 Chronic-Hepatitis-B patients who had taken TDF antiviral therapy for 48 to 49 weeks were chosen between January 2018 and February 2020. They were further separated into two groups regarding to the following treatments：one continues TDF treatment while the other replaces with TAF. The comparison was made based on the clinic efficacy and renal safety from such two groups after a 48-week continuous medication. Results TAF group showed a statistical difference significantly better in HBV-DNA inhibition rate，ALT normalization rate，and HBeAg serum conversion with χ² = 10.250，P = 0.001 and χ² = 6.871，P = 0.009，and χ² = 3.881，P = 0.049 respectively. In terms of the safety，TAF group also demonstrates a difference significantly lower in the urinary α1 microglobulin abnormal rate with χ² = 13.703，P = 0.000. On the other hand，there was no significant difference in bloom β2 microglobulin among the groups owning to P values ≥ 0.05. Conclusion With the statistical comparison between TAF and TDF treatments in this clinic study，TAF is observed to have a stronger antiviral effectiveness，fewer side effects such as less induced harm to the renal function，and reduce the risks deriving from the liver cirrhosis and cancer. [ABSTRACT FROM AUTHOR]